# Scientific Hypothesis Synthesis & Evaluation
## Hypothesis Summary
**SCFA Deficiency Drives Microglial Hyperactivation via GPR43/NF-κB Dysregulation**
The hypothesis posits that gut dysbiosis depletes SCFA-producing commensals, reducing SCFA-mediated activation of microglial GPR43/GPR41 receptors and HDAC inhibition. This removes inhibitory checkpoints on NF-κB, permitting unchecked pro-inflammatory cytokine production.
---
## Dimension Scores
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| **Mechanistic Plausibility** | **0.81** | Logically coherent pathway; integrates receptor-mediated G-protein signaling with epigenetic regulation. GPR43/41 → NF-κB axis is biologically supported, though HDAC3 specificity in microglia requires validation. |
| **Evidence Strength** | **0.72** | Strong biochemical evidence for SCFA-HDAC-NF-κB relationships. Moderate evidence from germ-free/antibiotic mouse models. Limited direct human evidence; causality in neurodegeneration remains associative. |
| **Novelty** | **0.65** | Modestly novel; builds on established gut-brain axis literature. The dual braking mechanism (receptor + epigenetic) adds conceptual refinement rather than paradigm shift. |
| **Feasibility** | **0.78** | Highly testable in animal models (GF mice, FMT, SCFA supplementation). Human translational studies are feasible but expensive. GPR43 knockout/agonist studies are technically mature. |
| **Therapeutic Potential** | **0.84** | High potential: butyrate supplementation, prebiotics, probiotics, GPR43 agonists. Blood-brain barrier